Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1
{{output}}
Objectives: To evaluate the efficacy of guselkumab through four years of continuous treatment for psoriasis. Methods: In the phase 3 VOYAGE 1 t... ...
